ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.
Ding
Changhai
C
University of Tasmania, Menzies Research Institute, 199 Macquarie Street, Hobart, Tasmania 7000, Australia. changhai.ding@utas.edu.au
Xu
Jianhua
J
Li
Jun
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018664:Interleukin-12 / Q000276:immunology*; D018793:Interleukin-13 / Q000276:immunology*; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018793:Interleukin-13; D018664:Interleukin-12; C544528:briakinumab